• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Pluri Inc.

    3/19/25 4:10:09 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PLUR alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001158780
    PLURISTEM THERAPEUTICS INC
    PLURISTEM LIFE SYSTEMS INC
    AI SOFTWARE INC
    PLURISTEM THERPEUTICS INC.
    PLURISTEM LIFE SYSTEMS INC.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Pluri Inc.
    Jurisdiction of Incorporation/Organization
    NEVADA
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Pluri Inc.
    Street Address 1 Street Address 2
    MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    HAIFA ISRAEL 3508409 972-74-710-7171

    3. Related Persons

    Last Name First Name Middle Name
    Yanay Yaky
    Street Address 1 Street Address 2
    Matam Advanced Technology Park Building No. 5
    City State/Province/Country ZIP/PostalCode
    Haifa ISRAEL 3508409
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Chief Executive Officer, President and Director
    Last Name First Name Middle Name
    Zalts Liat
    Street Address 1 Street Address 2
    Matam Advanced Technology Park Building No. 5
    City State/Province/Country ZIP/PostalCode
    Haifa ISRAEL 3508409
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Financial Officer
    Last Name First Name Middle Name
    Aberman Zami
    Street Address 1 Street Address 2
    Matam Advanced Technology Park Building No. 2
    City State/Province/Country ZIP/PostalCode
    Haifa ISRAEL 3508409
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Chairman of the Board of Directors
    Last Name First Name Middle Name
    Birger Doron
    Street Address 1 Street Address 2
    Matam Advanced Technology Park Building No. 2
    City State/Province/Country ZIP/PostalCode
    Haifa ISRAEL 3508409
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Levi Rami
    Street Address 1 Street Address 2
    Matam Advanced Technology Park Building No. 2
    City State/Province/Country ZIP/PostalCode
    Haifa ISRAEL 3508409
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Shemesh-Ramussen Maital
    Street Address 1 Street Address 2
    Matam Advanced Technology Park Building No. 2
    City State/Province/Country ZIP/PostalCode
    Haifa ISRAEL 3508409
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Weinstein Alejandro
    Street Address 1 Street Address 2
    Matam Advanced Technology Park Building No. 2
    City State/Province/Country ZIP/PostalCode
    Haifa ISRAEL 3508409
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-02-03    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    None None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    None
    City State/Province/Country ZIP/Postal Code
    None Unknown 00000
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    CALIFORNIA

    13. Offering and Sales Amounts

    Total Offering Amount $3,500,000 USD
    or    Indefinite
    Total Amount Sold $3,500,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Pluri Inc. /s/ Liat Zalts Liat Zalts Chief Financial Officer 2025-03-19

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $PLUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLUR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shemesh-Rasmussen Maital was granted 11,173 shares, increasing direct ownership by 154% to 18,445 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:19 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Levi Rami Avraham was granted 11,173 shares, increasing direct ownership by 156% to 18,314 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:22 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Zalts Liat was granted 67,857 shares, increasing direct ownership by 319% to 89,107 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:17 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

      Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal year 2025 compared to the same period in fiscal year 2024, driven by its CDMO and AgTech businesses, and is advancing new food tech partnerships and licensing opportunities HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today issued the following shareholder update from Chief Executive Officer an

      5/15/25 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DarioHealth Announces CFO Transition

      NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity. "It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished,

      4/21/25 8:30:00 AM ET
      $BNRG
      $DRIO
      $PLUR
      Building Products
      Industrials
      Medical/Dental Instruments
      Health Care
    • Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel

      Latest granted patents reinforce Pluri's position as a leader in Mucosal-Associated Invariant T ("MAIT") cell-based cell therapies for solid cancersPluri's MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, "off-the-shelf" therapy for cancer patientsPluri's MAIT platform addresses the global immune cell engineering market, projected to reach approximately $11.7 billion by 2030, and the global cancer immunotherapy market, calculated at $136 billion in 2025In addition to MAIT cells, Pluri's platform also supports the expansion of Tumor Infiltrating Lymphocytes (TILs), further broadening the scope of potential immune cell ther

      4/10/25 8:30:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Leadership Updates

    Live Leadership Updates

    See more
    • Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

      HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of

      3/6/24 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

      HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023.  Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t

      7/13/23 2:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pluri Inc.

      10-Q - Pluri Inc. (0001158780) (Filer)

      5/13/25 4:03:23 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Inc. filed SEC Form 8-K: Other Events

      8-K - Pluri Inc. (0001158780) (Filer)

      5/8/25 8:30:07 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Inc. filed SEC Form 8-K: Shareholder Director Nominations

      8-K - Pluri Inc. (0001158780) (Filer)

      4/29/25 4:00:31 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      2/13/24 4:34:49 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      2/1/24 4:02:29 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      9/15/23 4:00:03 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Financials

    Live finance-specific insights

    See more
    • BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

      Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil

      11/11/24 6:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care